Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | TTK | P33981 | 1/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.68 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.68 |
| ▸ | GPR142 | Q7Z601 | 15/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10062827 | 0.88 | ITK (0.65) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL10062887 | 0.84 | GPR142 (0.58) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL11351579 | 0.83 | ITK (0.64) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL21637786 | 0.82 | ITK (0.64) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL11456181 | 0.82 | ITK (0.67) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL11456925 | 0.82 | ITK (0.73) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL10062814 | 0.81 | ITK (1.00) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL11351031 | 0.81 | ITK (0.62) | ITKAURKATTKAURKBINCENP | |
| SCHEMBL2686213 | 0.81 | GPR142 (1.00) | GPR142 | |
| SCHEMBL2686207 | 0.81 | GPR142 (1.00) | GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831168-B1 | PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. | VERTEX PHARMA (US) | 2014-07-02 | — | — | EP | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-18 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338597-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-26 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101770-B2 | Pyridones useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190699-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885AURKA 97/4885TTK 242/4885 |
| US-20130184259-A1 | PYRIDONES USEFUL AS INHIBITORS OF KINASES | MAP3K20, MAP3K6, MAP3K5 | ITK 393/4885AURKA 97/4885TTK 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.